Dr.ย Zefeiย Jiang
MD, PhD
Chief Physician & Professor, Medical Oncology
corporate_fareFifth Medical Center, PLA General Hospital, Beijing
Zefei Jiang
MD, PhD
Prof. Zefei Jiang is one of China's most prominent breast cancer medical oncologists, serving as Chief Physician, Professor, and Deputy Director of the Oncology Department at the Fifth Medical Center of PLA General Hospital in Beijing. He graduated from First Military Medical University in 1987 and has dedicated his career to advancing breast cancer diagnosis, systemic therapy, and translational research.
Prof. Jiang's clinical expertise spans systemic therapy for early, locally advanced, recurrent, metastatic, HER2-positive, hormone receptor-positive, and triple-negative breast cancer. He has played a central role in shaping national breast cancer treatment standards in China through the CSCO Breast Cancer Diagnosis and Treatment Guidelines, which have been widely adopted and published internationally since 2017. His research extends into immunotherapy, targeted therapy, liquid oncology, molecular precision medicine, and artificial intelligence-assisted oncology. He serves as Vice President and Secretary-General of the Chinese Society of Clinical Oncology and Chairman of the CSCO Breast Cancer Expert Committee, reflecting his national leadership in the field.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert opinion from Prof. Jiang, subject to hospital availability and case acceptance.
Why Consider Prof. Zefei Jiang?
Prof. Jiang combines decades of clinical breast cancer expertise with a leading role in national guideline development and major international clinical trials, making him a reference point for complex breast cancer cases in China.
Areas of Specialisation
Systemic therapy, immunotherapy, and precision medicine for breast cancer
Breast Cancer Systemic Therapy
Comprehensive management of all breast cancer subtypes using evidence-based and guideline-driven systemic approaches.
- arrow_rightAnti-HER2 targeted therapy planning and sequencing
- arrow_rightSystemic therapy for early and metastatic HER2-positive disease
- arrow_rightEvaluation of novel anti-HER2 agents and combinations
- arrow_rightImmunotherapy-based regimens for advanced TNBC
- arrow_rightChemotherapy protocols for neoadjuvant and metastatic settings
- arrow_rightClinical trial-based treatment pathways including toripalimab combinations
- arrow_rightEndocrine therapy selection and sequencing
- arrow_rightCDK4/6 inhibitor-based treatment planning
- arrow_rightManagement of endocrine-resistant advanced disease
Precision Oncology & Emerging Therapies
Biomarker-driven and research-supported approaches to personalised breast cancer treatment.
- arrow_rightPD-1/PD-L1 checkpoint inhibitors in advanced TNBC
- arrow_rightBiomarker selection for immunotherapy candidacy
- arrow_rightCombination immunotherapy and chemotherapy protocols
- arrow_rightLiquid biopsy and circulating tumour DNA analysis
- arrow_rightAI-assisted clinical decision support for treatment planning
- arrow_rightGenomic and molecular profiling-guided therapy selection
Procedures Performed
Medical oncology services and treatment approaches for breast cancer
Systemic Cancer Treatment
Medical OncologyEvidence-based systemic therapy for all stages and subtypes of breast cancer, guided by CSCO and international guidelines.
Immunotherapy Administration
Targeted TherapyCheckpoint inhibitor and combination immunotherapy regimens for eligible breast cancer patients.
Precision Diagnostics & Treatment Planning
DiagnosisMolecular and biomarker-guided workup to inform personalised breast cancer treatment decisions.
Second Opinion & Complex Case Review
Second OpinionIndependent expert review of breast cancer diagnosis, pathology, and treatment plans for patients and referral physicians.
Research & Publications
Clinical trial leadership, peer-reviewed publications, and guideline contributions
Prof. Jiang has led and contributed to landmark breast cancer research in China, including major clinical trials, international guideline publications, and AI-assisted oncology studies. He has edited more than ten professional oncology books and participated in eleven national, military, and Beijing-level research projects.
Prof. Jiang's research spans clinical trials, guideline development, and AI-assisted precision oncology. A more detailed publication list is available via PubMed and Google Scholar.
Education & Training
Prof. Jiang graduated from First Military Medical University in 1987 and has since built his academic career at PLA General Hospital, where he holds the rank of Professor and doctoral supervisor.
Clinical Experience
Prof. Jiang has worked in oncology clinical care and scientific research since graduating in 1987, with his career centred at PLA General Hospital in Beijing. He currently serves as Deputy Director of the Oncology Department at the Fifth Medical Center and holds senior national leadership roles in the Chinese Society of Clinical Oncology.
Languages & International
Prof. Jiang conducts consultations in the following languages.
CancerFax can coordinate certified medical interpreters for English and other languages to support international patients consulting Prof. Jiang.
CancerFax can coordinate professional medical interpreter support for international patients consulting in English or other languages.
How CancerFax Helps You Access Dr. Zefei Jiang
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Zefei Jiang's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Zefei Jiang's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Zefei Jiang before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Zefei Jiang's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Zefei Jiang's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Zefei Jiang's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Zefei Jiang
Prof. Jiang specialises exclusively in breast cancer, including HER2-positive breast cancer, triple-negative breast cancer, hormone receptor-positive breast cancer, metastatic and recurrent breast cancer, and breast cancer with brain metastases. He is one of China's leading breast cancer medical oncologists.
Prof. Jiang is based at the Fifth Medical Center of PLA General Hospital in Beijing, China, where he serves as Chief Physician and Deputy Director of the Oncology Department.
International consultation availability is subject to hospital acceptance and case review. CancerFax can assist international patients by coordinating medical report submission, case preparation, and consultation support with Prof. Jiang's team, subject to hospital availability.
Submit your medical reports through CancerFax using the 'Send Your Reports' button. The CancerFax team will review your documents, prepare the case for submission, and coordinate the next steps with the hospital, subject to availability.
Yes. Prof. Jiang served as principal investigator in the TORCHLIGHT phase 3 trial, which evaluated toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer. The study was published in Nature Medicine. His ongoing research also includes biomarker-driven and AI-assisted breast cancer treatment approaches.
Prof. Jiang has played a central role in the development and publication of the CSCO Breast Cancer Diagnosis and Treatment Guidelines since 2017. He serves as Chairman of the CSCO Breast Cancer Expert Committee and Vice President and Secretary-General of the Chinese Society of Clinical Oncology, making him one of the principal architects of breast cancer treatment standards in China.
Connect with Zefei Jiang Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.